ESMO 2026: Real-world treatment patterns in metastatic melanoma: Comparison of data from the Central and South Eastern European Registry (CSEEREG) and the Danish Metastatic Melanoma Database (DAMMED)
Authors: D. Herceg, C. Ruhlmann, D. Štulhofer Buzina et. al.
ESMO 2026: Impact on survival of early discontinuation of immune checkpoint inhibitors after objective response in melanoma
Authors: I. Mansfield Noringriis, R. Schou Jurlander, K. Suijkerbuijk et. al.
ESMO 2026: Effectiveness of Dabrafenib plus Trametinib as second-line therapy in comparison to first line in BRAFV600 mutated metastatic melanoma patients. A EUMelaReg real-world study
Authors: P. Mohr, E. Ellebaek, M. Weichenthal et. al.
Cancers 2026: COMBI-EU: Real-World Evidence on Adverse Event Management and Time on Therapy with Adjuvant Dabrafenib Plus Trametinib in Patients with BRAF V600-Mutant Melanoma
Authors: M. Weichenthal, D. Debus, L. Zimmer et.al.
EJC Skin Cancer 2026: BRAF/MEK inhibitor rechallenge in patients with non-resectable or metastatic BRAF V600-mutated melanoma: A stratified, controlled, retrospective EUMelaReg multicenter study
Authors: M. Weichenthal, I Gavrilova, P. Mohr et. al.
ESMO 2026: Decision Making on Adjuvant Anti-PD1 Treatment in Stage IIB/IIC Melanoma in Europe -DECIDE-II-
Authors: M. Weichenthal, I. Gavrilova, H. Löffler et. al.
ESMO 2026: MELASITE: UV Exposure Pattern as a Clinical Surrogate for Immunotherapy Response in Advanced Melanoma
Authors: N. Asher, J. Mangana, P. Mohr et. al.
ASCO 2026: Outcome of adjuvant BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600K- compared to V600E-mutated melanoma
Authors: M. Weichenthal, E. Ellebaek, P. Mohr et. al.
EJC Skin Cancer 2026: Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study
Authors: E. Ellebaek, M. Weichenthal, I. Gavrilova et. al.